The Office Action mailed July 16, 2008, has been carefully considered. The present

Amendment is intended to be a complete response thereto and to place the case in condition for

allowance.

Claims 32-73 are pending. Claims 32-55 and 68-73 have been withdrawn from

consideration by the Examiner as being drawn to a non-elected invention. Claims 1-31 have

been cancelled. Claim 56 has been amended. Support for the amendment is found, inter alia, in

the specification on page 18, fifth paragraph. Claims 74-75 have been added. Support for the

amendment is found, *inter alia*, in the specification on page 9, third paragraph.

THE CLAIMS ARE NOT INDEFINITE

Claim 56 stands rejected under 35 U.S.C. § 112, second paragraph, as being indefinite.

Applicants respectfully traverse the rejection.

The Examiner alleges that the recitation of "Form I" is not an universal identification of

the compound. Applicants respectfully submit that "Form I crystals of (+)-(S)-clopidogrel

hydrogen sulphate" is defined in the specification and is generally accepted and has a clear

meaning in the art. First, the specification on page 4, second paragraph, discloses that Form I is

the same as that taught in WO 99/65915. Second, the prior art is replete with references to Form

I clopidogrel hydrogen sulfate identifying the same crystalline form. For example, following

U.S. patents extensively refer to Form I clopidogrel hydrogen sulfate (also known as clopidogrel

bisulfate): 7,074,928; 6,767,913; 6,800,759; and 7,291,735. Therefore, contrary to the

Examiner's allegation, Form I clopidogrel hydrogen sulfate is a well known an commonly

accepted identification of a crystalline form of clopidogrel hydrogen sulfate, evidenced by its

10

U.S. Application Serial No.: 10/591,657

Response to Office Action mailed July 16, 2008

Attorney Docket No.: 124907.0106

many references in the art. Accordingly, Applicants respectfully submit that claim 56 is not

indefinite and request withdrawal of the rejection.

THE CLAIMS ARE ALLOWABLE

Applicants gratefully acknowledge the Examiner indicating claims 56-67 as being

allowable if rewritten to overcome the rejection under 35 U.S.C. § 112, second paragraph.

Applicants respectfully submits that because claim 56 is not indefinite (as discussed above), all

claims are now in condition for allowance.

**CONCLUSION** 

Applicants have responded to the Office Action mailed July 16, 2008. All pending

claims are now believed to be allowable and favorable action is respectfully requested.

In the event that there are any questions relating to this Amendment or to the application

in general, it would be appreciated if the examiner would telephone the undersigned attorney

concerning such questions so that the prosecution of this application may be expedited.

Please charge any shortage or credit any overpayment of fees to BLANK ROME LLP,

Deposit Account No. 23-2185 (124907.0106). In the event that a petition for an extension of

time is required to be submitted herewith and in the event that a separate petition does not

accompany this response, Applicants hereby petition under 37 C.F.R. 1.136(a) for an extension

of time for as many months as are required to render this submission timely.

11

124907.00106/35879775v.1

U.S. Application Serial No.: 10/591,657

Response to Office Action mailed July 16, 2008 Attorney Docket No.: 124907.0106

Any fees due are authorized above.

Respectfully submitted,

Date: October 15, 2008 By: /Minh-Quan K. Pham, Ph.D./

Minh-Quan K. Pham, Ph.D. Registration No. 50,594

BLANK ROME LLP Watergate 600 New Hampshire Ave., NW Washington, DC 20037 Telephone: 202-772-5800

Facsimile: 202-572-1400